Guardant Health
217 hedge funds and large institutions have $6.57B invested in Guardant Health in 2019 Q2 according to their latest regulatory filings, with 89 funds opening new positions, 81 increasing their positions, 27 reducing their positions, and 19 closing their positions.
368% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 19
200% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 27
45% more funds holding
Funds holding: 150 → 217 (+67)
42% more capital invested
Capital invested by funds: $4.63B → $6.57B (+$1.94B)
12.8% more ownership
Funds ownership: 70.23% → 83.02% (+13%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
29% less call options, than puts
Call options by funds: $41.9M | Put options by funds: $59M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$222M |
| 2 |
Jennison Associates
New York
|
+$158M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$133M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$94.2M |
| 5 |
Coatue Management
New York
|
+$91.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$118M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$19.3M |
| 3 |
N
Natixis
Paris,
France
|
-$5.02M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$3.35M |
| 5 |
NIT
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
|
-$2.91M |
GH Hedge Fund Activity: Q2 2019 in Review
217 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Guardant Health (GH) for Q2 2019, worth a combined $6.57B — up 42% from $4.63B a quarter earlier.
Buyers outnumbered sellers: 89 funds opened new GH positions and 19 closed out — a net gain of 70 holders — while 81 added to existing stakes and 27 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $222M. The largest seller was OrbiMed, exiting entirely with an estimated $118M sold.
- 217 institutional investors held Guardant Health (GH) as of Q2 2019, up from 150 in Q1 2019.
- Funds reported $6.57B of Guardant Health stock for Q2 2019, up 42% quarter-over-quarter.
- 89 funds opened new Guardant Health positions in Q2 2019 and 19 closed out, a net change of +70 holders.
- The largest Guardant Health buyer in Q2 2019 was Morgan Stanley, an estimated $222M added.
- The largest Guardant Health seller in Q2 2019 was OrbiMed, an estimated $118M sold.
Based on aggregated 13F filings for Q2 2019.